Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Amyvid Clear all
Completed Phase 2 Interventional Results available

Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients

NCT00857532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects

NCT04474405
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Flortaucipir F18, Brain PET Scan, Whole body PET scan, Florbetapir F 18, Brain MRI
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
20 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Cypress, California • Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2020 · Synced Oct 20, 2026, 2:26 PM EDT
Completed No phase listed Observational

Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials

NCT02918539
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
florbetapir F 18 PET scan
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
75
States / cities
Glendale, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography

NCT01683825
View directory record Official record
Conditions
Cardiac Amyloidosis
Interventions
F-18 florbetapir PET
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

A Preliminary Study of 18F-AV-45 in Alzheimer's Disease and Healthy Elderly Volunteers

NCT01565291
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
3
States / cities
Baltimore, Maryland • North East, Maryland • Long Branch, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Reader Training Processes

NCT02051790
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
Not listed
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 20, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

NCT02051764
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Florbetapir F 18, Brain PET Scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

NCT02370524
View directory record Official record
Conditions
Alzheimer's Disease (AD)
Interventions
[18F]T807
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
20 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 20, 2026, 2:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 2

NCT01231971
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), Significant Memory Concern (SMC), Early Mild Cognitive Impairment (EMCI), Late Mild Cognitive Impairment (LMCI)
Interventions
Florbetapir, Flortaucipir
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07

NCT01447719
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Tau Imaging of Chronic Traumatic Encephalopathy

NCT02191267
View directory record Official record
Conditions
Chronic Traumatic Encephalopathy
Interventions
[F18]-T807, [F18]-Florbetapir, MRI/MRS, Genetic Analysis for Genetic Risk Score for Tau.
Radiation · Device · Genetic
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 69 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 20, 2026, 2:26 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 4

NCT05617014
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
Radiation
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Alzheimer's Disease (AD) and Healthy Volunteers

NCT01565343
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
New Haven, Connecticut • Hallandale, Florida • West Palm Beach, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Oct 20, 2026, 2:26 PM EDT
Not yet recruiting Phase 1 Interventional

Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

NCT06600880
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 20, 2026, 2:26 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT07843459
View directory record Official record
Conditions
Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Interventions
LY4560736, Placebo, Florbetapir F18, Florbetaben F 18
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
13
States / cities
Anaheim, California • Irvine, California • Los Alamitos, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 2:26 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Entire-body PET Scans for Multiple Sclerosis

NCT04390009
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Entire-body PET-CT scans, Amyvid radiopharmaceutical
Diagnostic Test · Drug
Lead sponsor
Brain Health Alliance
Other
Eligibility
25 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Ladera Ranch, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Doses of 18F-AV-45 in Alzheimer's Disease and Healthy Volunteers

NCT01565330
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
West Palm Beach, Florida • North East, Maryland • Clementon, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45)

NCT00857506
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Scottsdale, Arizona • Tucson, Arizona • Costa Mesa, California + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

NCT01703702
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
florbetapir (18F)
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study

NCT01834716
View directory record Official record
Conditions
Alzheimer's Disease Prevention
Interventions
Aerobic vs. Non-Aerobic exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

NCT01767493
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[18F]Florbetapir PET imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

Potential of Florbetapir F 18 PET to Inform Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline

NCT01400425
View directory record Official record
Conditions
Progressive Cognitive Decline
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 20, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Florbetapir Calibration to the Centiloid Scale

NCT02120664
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Florbetapir (18F), 11C-PiB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 20, 2026, 2:26 PM EDT